Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01109524

Public ClinicalTrials.gov record NCT01109524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.

Study identification

NCT ID: NCT01109524
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2010 (Type not available)
Primary completion: Sep 2012 (Actual)
Completion: Sep 2012 (Actual)
Last update posted: Dec 24, 2015

2010 – 2012

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
Donald W. Hill M.D., P.C.	Casa Grande	Arizona	85122	—
Beverly Hills Cancer Center	Beverly Hills	California	90211	—
Cancer Care Institute	Los Angeles	California	90036	—
Northern California Hematology & Oncology	Oakland	California	94609	—
Sharp Clinical Oncology Research	San Diego	California	92123	—
Broward Oncology Associates, P.A.	Fort Lauderdale	Florida	33308	—
Elite Research Institute	Miami	Florida	33125	—
Edward H. Kaplan, MD & Associates	Skokie	Illinois	60076	—
Fairview Southdale Medical Oncology Clinic	Edina	Minnesota	55435	—
Mid Dakota Clinic, Pc	Bismarck	North Dakota	58501	—
Temple University Hospital	Philadelphia	Pennsylvania	19140	—
University Medical Center	Lubbock	Texas	79415	—
Columbia Basin Hematology and Oncology	Kennewick	Washington	99336	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01109524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 24, 2015 · Synced Nov 8, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01109524 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →